Company: ANIX
Filing Date: 2025-09-10
Form Type: 10-Q
Source: 0001493152-25-013000
Chunk: 2

Company: Anixa Biosciences Inc
Filing Date: 2025-09-10
Form: 10-Q
Item: Part I, Item 1
Chunk 2
---

     1,667  
     4,896  
     5,748 
  
    Total
    operating expenses 
     2,436  
     3,592  
     8,825  
     10,668 

    Loss
    from operations 
     (2,436) 
     (3,592) 
     (8,825) 
     (10,668)

    Interest
    income 
     156  
     277  
     519  
     883 

    Net
    loss 
     (2,280) 
     (3,315) 
     (8,306) 
     (9,785)

    Less:
    Net loss attributable to noncontrolling interest 
     (22) 
     (38) 
     (74) 
     (114)

    Net
    loss attributable to common shareholders 
    $(2,258) 
    $(3,277) 
    $(8,232) 
    $(9,671)

    Net
    loss per common share attributable to common shareholders: 

    Basic
    and diluted 
    $(0.07) 
    $(0.10) 
    $(0.25) 
    $(0.30)

    Weighted
    average common shares outstanding: 

    Basic
    and diluted 
     32,476  
     32,054  
     32,293  
     31,804 

The
accompanying notes are an integral part of these condensed consolidated financial statements.

2

ANIXA
BIOSCIENCES, INC. AND SUBSIDIARIES

CONDENSED
CONSOLIDATED STATEMENTS OF EQUITY

(in
thousands, except share data)

FOR
THE THREE MONTHS ENDED JULY 31, 2025 (UNAUDITED)

    Shares  
    Par
    Value  
    Paid-in
    Capital  
    Accumulated
     Deficit  
    Treasury
     Stock  
    Shareholders’
    Equity  
    controlling
     Interest  
    Total
    Equity 

    Common
    Stock  
    Additional  

    Total  
    Non-  

    Shares  
    Par
    Value  
    Paid-in
    Capital  
    Accumulated
     Deficit